Page 1 | Search Results | Blood | American Society of Hematology

1-13 of 13

Sort by

Sort Order Select

Journal Articles

Anti-Leukemic Activity of Luveltamab Tazevibulin (LT, STRO-002), a Novel Folate Receptor-α (FR-α)-Targeting Antibody Drug Conjugate (ADC) in Relapsed/Refractory CBF2AT3::GLIS2 AML

Blood (2023) 142 (Supplement 1): 4295.

https://doi.org/10.1182/blood-2023-180141

Published: 2023

Journal Articles

Results from the Phase 1 Portion of a Trial of Oral Ixazomib Combined with Chemotherapy in Relapsed/Refractory Acute Lymphoblastic Leukemia or Lymphoma in Children, Adolescents and Young Adults: A Report from the Therapeutic Advances in Childhood Leukemia and Lymphoma (TACL) Consortium

Eric S. Schafer, Yueh-Yun Chi, Jemily Malvar, Teresa Rushing, Andrew Doan, Holly L. Pacenta, Reuven J. Schore, Richard Sposto, Roy Leong, Paul S. Gaynon, Jeffrey E. Rubnitz, Julio C. Barredo, Tamra Slone, Melinda Pauly, Alan S. Wayne, Deepa Bhojwani, Terzah M. Horton

Blood (2023) 142 (Supplement 1): 2872.

https://doi.org/10.1182/blood-2023-180414

Published: 2023

Journal Articles

A Pilot Study of Azacitidine As Epigenetic Priming for Chemotherapy in Infants Less Than 1 Year of Age with KMT2A -Rearranged Acute Lymphoblastic Leukemia (ALL); Results from the Children's Oncology Group (COG) Trial AALL15P1

Erin Guest, John Kairalla, Meenakshi Devidas, Emily Hibbitts, Andrew J. Carroll, Nyla A. Heerema, Holly Kubaney, Amanda August, Melinda Pauly, Daniel Wechsler, Rodney R. Miles, Joel M. Reid, Cynthia Kihei, Lia Gore, Elizabeth A. Raetz, Stephen P. Hunger, Mignon L. Loh, Patrick A. Brown

Blood (2022) 140 (Supplement 1): 3256–3257.

https://doi.org/10.1182/blood-2022-167765

Published: 2022

Journal Articles

Anti-Leukemic Activity of STRO-002 a Novel Folate Receptor-α (FR-α)-Targeting ADC in Relapsed/Refractory CBF2AT3-GLIS2 AML

Blood (2022) 140 (Supplement 1): 159–161.

https://doi.org/10.1182/blood-2022-162842

Published: 2022

Journal Articles

Phase 1b Study of Carfilzomib in Combination with Induction Chemotherapy in Children with Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL)

Michael J. Burke, David S. Ziegler, Francisco Bautista, Andishe Attarbaschi, Lia Gore, Franco Locatelli, Maureen M. O'Brien, Melinda Pauly, Mihaela Obreja, Christopher L. Morris, Andre Baruchel

Blood (2021) 138 (Supplement 1): 1235.

https://doi.org/10.1182/blood-2021-147588

Published: 2021

Journal Articles

Single Cell Transcriptomics Revealed AML and Non-AML Cell Clusters Relevant to Relapse and Remission in Pediatric AML

Beena E Thomas, Pruthvi Perumalla, MS, Swati S Bhasin, PhD, Debasree Sarkar, PhD, Bhakti Dwivedi, PhD, Sunita I Park, MD, Deborah DeRyckere, BS,PhD, Curtis J. Henry, PhD, Sunil S. Raikar, MD, Christopher C. Porter, MD, Melinda Pauly, MD, Ryan J Summers, MD, Sharon M. Castellino, MD MSc, Daniel S. Wechsler, MD PhD, Douglas K Graham, MD PhD, Manoj Bhasin, PhD

Blood (2020) 136 (Supplement 1): 24–25.

https://doi.org/10.1182/blood-2020-142513

Published: 2020

Journal Articles

Phase 1b Study of Carfilzomib in Combination with Induction Chemotherapy in Children with Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL)

Michael J. Burke, MD, David S. Ziegler, MBBS, FRACP, MD, Francisco José Bautista Sirvent, MD PhD, Andishe Attarbaschi, MD, Lia Gore, MD, Franco Locatelli, MD PhD, Maureen M O'Brien, MD, Melinda Pauly, MD, Mihaela Obreja, PhD, Christopher L. Morris, PhDMD, Andre Baruchel, MD

Blood (2019) 134 (Supplement_1): 3873.

https://doi.org/10.1182/blood-2019-127350

Published: 2019

Journal Articles

Matched Targeted Therapy for Pediatric Patients with Relapsed, Refractory or High-Risk Leukemias: A Report from the LEAP Consortium

Blood (2018) 132 (Supplement 1): 261.

https://doi.org/10.1182/blood-2018-99-116948

Published: 2018

Journal Articles

Phase I Study of the Selinexor in Relapsed/Refractory Childhood Acute Leukemia

Andrew E. Place, MD PhD, Traci M. Blonquist, MS, Elliot Stieglitz, MD, Todd M Cooper, DO, Lia Gore, MD, Richard Aplenc, MD PhD, Mignon L. Loh, MD, Melinda Pauly, MD, Rachel E. Rau, MD, Michael J. Burke, MD, Julia Etchin, PhD, A. Thomas Look, MD, Maria Luisa Sulis, MD, Lewis B. Silverman, MD

Blood (2018) 132 (Supplement 1): 1405.

https://doi.org/10.1182/blood-2018-99-116689

Published: 2018

Journal Articles

Absence of Silent Inactivation Using Intravenous Pegaspargase in Pediatric Acute Lymphoblastic Leukemia

Sarayu Kumar, BA, BSPH, Curtis D Travers, MPH, John Bergsagel, MD, Frank G Keller, MD, Melinda Pauly, MD, Himalee Sabnis, MDMS, Sharon M. Castellino, MD MSc, Glen Lew, MD

Blood (2017) 130 (Supplement 1): 100.

https://doi.org/10.1182/blood.V130.Suppl_1.100.100

Published: 2017

Journal Articles

A Phase 1 Study of Denintuzumab Mafodotin (SGN-CD19A) in Adults with Relapsed or Refractory B-Lineage Acute Leukemia (B-ALL) and Highly Aggressive Lymphoma

Amir T Fathi, MD, Uma Borate, MD, Daniel J. DeAngelo, MD PhD, Maureen M. O'Brien, MD, Tanya Trippett, MD, Bijal D Shah, Gregory A. Hale, MD, James M. Foran, MD, Lewis B. Silverman, MD, Raoul Tibes, MD PhD, Stuart Cramer, D.O., Melinda Pauly, MD, Stella Kim, Ana Kostic, MD, Xiaohui Huang, Yang Pan, PhD, Robert Chen

Blood (2015) 126 (23): 1328.

https://doi.org/10.1182/blood.V126.23.1328.1328

Published: 2015

Journal Articles

Preliminary Report of the Phase 1 Study of the DOT1L Inhibitor, Pinometostat, EPZ-5676, in Children with Relapsed or Refractory MLL-r Acute Leukemia: Safety, Exposure and Target Inhibition

Neerav Shukla, MD, Maureen M. O'Brien, MD, Lewis B. Silverman, MD, Melinda Pauly, MD, Cynthia Wetmore, MD PhD, Mignon L. Loh, MD, James A. Whitlock, MD, Patrick Brown, MD, Blythe Thomson, MD, Stephen J. Blakemore, PhD, Scott Daigle, Patricia Pimentel, Nigel J. Waters, PhD, Andrei V Krivstov, PhD, Richard Koche, PhD, Scott A. Armstrong, MD PhD, Peter T Ho, PhD MD, Lia Gore, MD

Blood (2015) 126 (23): 3792.

https://doi.org/10.1182/blood.V126.23.3792.3792

Published: 2015

Journal Articles

Phase Ib Trial of the mTOR Inhibitor Everolimus Given in Combination with Multiagent Chemotherapy in Relapsed Acute Lymphoblastic Leukemia

Andrew E. Place, MDPhD, Yana Pikman, MD, Kristen Stevenson, MS, Marian H. Harris, MD PhD, Todd M. Cooper, DO, Lia Gore, MD, Nobuko Hijiya, MD, Mignon L. Loh, MD, Melinda Pauly, MD, Maria Luisa Sulis, MD, Donna S Neuberg, ScD, Kimberly Stegmaier, MD, Stephen E. Sallan, MD, Lewis B. Silverman, MD

Blood (2015) 126 (23): 3765.

https://doi.org/10.1182/blood.V126.23.3765.3765

Published: 2015

NARROW

Anti-Leukemic Activity of Luveltamab Tazevibulin (LT, STRO-002), a Novel Folate Receptor-α (FR-α)-Targeting Antibody Drug Conjugate (ADC) in Relapsed/Refractory CBF2AT3::GLIS2 AML

Results from the Phase 1 Portion of a Trial of Oral Ixazomib Combined with Chemotherapy in Relapsed/Refractory Acute Lymphoblastic Leukemia or Lymphoma in Children, Adolescents and Young Adults: A Report from the Therapeutic Advances in Childhood Leukemia and Lymphoma (TACL) Consortium

A Pilot Study of Azacitidine As Epigenetic Priming for Chemotherapy in Infants Less Than 1 Year of Age with KMT2A -Rearranged Acute Lymphoblastic Leukemia (ALL); Results from the Children's Oncology Group (COG) Trial AALL15P1

Anti-Leukemic Activity of STRO-002 a Novel Folate Receptor-α (FR-α)-Targeting ADC in Relapsed/Refractory CBF2AT3-GLIS2 AML

Phase 1b Study of Carfilzomib in Combination with Induction Chemotherapy in Children with Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL)

Single Cell Transcriptomics Revealed AML and Non-AML Cell Clusters Relevant to Relapse and Remission in Pediatric AML

Phase 1b Study of Carfilzomib in Combination with Induction Chemotherapy in Children with Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL)

Matched Targeted Therapy for Pediatric Patients with Relapsed, Refractory or High-Risk Leukemias: A Report from the LEAP Consortium

Phase I Study of the Selinexor in Relapsed/Refractory Childhood Acute Leukemia

Absence of Silent Inactivation Using Intravenous Pegaspargase in Pediatric Acute Lymphoblastic Leukemia

A Phase 1 Study of Denintuzumab Mafodotin (SGN-CD19A) in Adults with Relapsed or Refractory B-Lineage Acute Leukemia (B-ALL) and Highly Aggressive Lymphoma

Preliminary Report of the Phase 1 Study of the DOT1L Inhibitor, Pinometostat, EPZ-5676, in Children with Relapsed or Refractory MLL-r Acute Leukemia: Safety, Exposure and Target Inhibition

Phase Ib Trial of the mTOR Inhibitor Everolimus Given in Combination with Multiagent Chemotherapy in Relapsed Acute Lymphoblastic Leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only